Pfizer said its investigational oral antibiotic gepotidacin delivered strong results in a pivotal phase 3 trial involving uncomplicated urinary tract infections caused by resistant bacteria. The company reported that the drug met all primary endpoints, with a 94% clinical and microbiological response rate.

The findings matter because urinary tract infections remain common, and treatment options are becoming more limited as antibiotic resistance rises. An effective oral option could help patients avoid more complex care and give clinicians another tool against hard-to-treat infections.

Pfizer has not yet said when it will seek regulatory approval based on the trial results, but the latest data add momentum to efforts to expand the antibiotic pipeline. Public health experts have long warned that resistant bacteria are outpacing the development of new treatments.

If approved, gepotidacin could become one of the few new oral antibiotics aimed at resistant UTIs, a condition that affects millions of people each year and can lead to more serious complications when first-line drugs fail.